Loading
A phase 2/3 trial of Cisplatin, Bevacizumab, Carboplatin in cervical cancer, run by Bio-Thera Solutions, now recruiting.
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer is a phase 2/3 interventional study registered as NCT06123884 by Bio-Thera Solutions, with 526 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-09. Interventions recorded: Recombinant humanized anti-PD-1 monoclonal antibody injection, Cisplatin, Bevacizumab Injection, carboplatin, Paclitaxel for Injection. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Cervical cancer, Cisplatin.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Anti-angiogenic therapy, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Cervical cancer, Cisplatin.
Shares Recurrent or metastatic cervical cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Recurrent or metastatic cervical cancer, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/